Aura Biosciences, a developer of nano-enabled drug delivery systems for the treatment of cancer, has secured $3.2 million in later-stage venture funding. Based in Cambridge, MA, Aura is focused on “the discovery of pseudo-viruses that selectively target tumors and metastases while sparing normal epithelium.” The recent financing comes more than a year after the closing of a successful $4.36 million Series A round from OXO Capital Valve Ventures.
